home
about us
our story
OUR MISSION
OUR VALUES
OUR PARTNERS
OUR SCIENTIFIC CO-FOUNDERS
OUR MANAGEMENT
OUR BOARD
TALENTS
science
F prau.
in Iflammatory Bowel Diseases
F prau.
in Cancer
MANUFACTURING LIVE BIOThERAPEUTICS
pipeline
Overview
Patients
Exl01 in Crohn's diseases
Exl01 in Cancer Immunotherapy
newsroom
PUBLICATIONS
contact
menu
about us
about us
Our story
Our mission
Our values
Our partners
Our Scientific Co-founders
Our management
Our board
Talents
science
science
Exl01
Crohn's Disease
Faecalibacterium Prausnitzii
in Inflammatory Bowel Diseases
Faecalibacterium Prausnitzii
immuno-oncology
Faecalibacterium Prausnitzii
in Recurrent
Clostridium difficile
Infections
Tryptophan metabolism
Manufacturing Live Biotherapeutics
pipeline
pipeline
OVERVIEW
Patients
EXL01 in Crohn’s Disease
EXL01 in Cancer Immunotherapy
EXL01 in Immuno-Oncology
EXL01 in recurrent
Clostridium difficile
infections
EXL02
EXL03
Regulatory Expertise
Intellectual Property
newsroom
newsroom
Corporate Presentation
Publications
News
Upcoming Events
contact
I-lab2018 Bpifrance
Jul 23, 2018
Exeliom Biosciences is awarded I-Lab2018 from Bpifrance
Back to news
Paris Biotech Santé
Sep 25, 2017
Exeliom Biosciences joins Paris Biotech Santé Incubator
Explore
#biotech #crohn'sdisease #clinicalstudy #milestones #immunotherapy #microbiome #livebiotherapeutics
Oct 19, 2023
Exeliom Biosciences Announces that the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 1 Clinical Trial of EXL01 in Crohn’s Disease
Explore
Series-A Biotech Exeliom Biosciences Nextbiotix
Jul 5, 2018
Exeliom Biosciences (formerly Nextbiotix) raises €7 million to tackle inflammatory bowel diseases
Explore
contact
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
